Temodar Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma
Condition: Glioblastoma Interventions: Biological: Autologous genetically modified gamma-delta T cells; Biological: Allogeneic genetically modified gamma-delta T cells Sponsor: In8bio Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 23, 2022 Category: Research Source Type: clinical trials

LITT Combined With Early Use of Temozolomide for Recurrent Glioblastomas
Condition: Recurrent Glioblastoma Interventions: Procedure: Laser interstitial thermal therapy; Drug: Temozolomide Sponsor: Beijing Tiantan Hospital Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 23, 2022 Category: Research Source Type: clinical trials

Glutamate Inhibitors in Glioblastoma
Condition: Glioblastoma Interventions: Drug: Gabapentin; Drug: Sulfasalazine; Drug: Memantine; Drug: Temozolomide; Radiation: Radiotherapy Sponsors: University of Zurich; Swiss National Science Foundation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 23, 2022 Category: Research Source Type: clinical trials